linjc16/ctgov huggingface dataset:
Total 102 Natural Orifice Specimen Extractions Following Laparoscopic Colorectal Resections

Study Overview
=================
Brief Summary
-----------------
In the development of surgical technique, laparoscopic surgery has created a major breaking point. Although laparoscopy (decreased hospital stay, decreased incisional hernia and wound infection rate…) provides a remarkable advantage compared to open surgery, the need for the extraction site incision could not bring the incision-related morbidity rates to the desired level. That's why SILS and natural hole surgery came to the fore. Colorectal surgery was also affected by this process, and the laparoscopic colectomy procedure combined with transrectal colon extraction was first performed in 1993 (1). Although its use increased gradually after this period, it could not reach the expected levels and this could not resolve the concerns on natural hole surgery. In this article, our aim is to present the single center results of the patients who performed the extraction with the NOSE method after laparoscopic colorectal surgery.

Official Title
-----------------
Total 102 Natural Orifice Specimen Extractions Following Laparoscopic Colorectal Resections

Conditions
-----------------
Incisional Hernia, Incision Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent laparoscopic - natural orifice colectomy. Exclusion Criteria: patients with missing data patients who underwent open colectomy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications due to incision and aesthetic score | Hernia, infection, hospital stay and aesthetic score | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
natural orifice surgery, minimally invasive surgery, colon cancer, laparoscopic colorectal
Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Study Overview
=================
Brief Summary
-----------------
Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Detailed Description
-----------------
This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Official Title
-----------------
Cytokine Production in Children With Asthma.

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African-American race, born in the U.S. Age 8-15 years Clinical diagnosis of asthma Subject is able to understand and follow verbal instructions in English Exclusion Criteria: Asthma exacerbation in the 4 weeks preceding the research visit Oral/IV steroid use in the 4 weeks preceding the research visit Upper or lower respiratory tract infection in the 4 weeks preceding the research visit Antibiotic use in the 4 weeks preceding the research visit Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing) Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with asthma<br>African American children with clinically diagnosed stable asthma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interleukin-13 from phytohemagglutinin activated peripheral blood mononuclear cells |  | 7 months (from the start to completion of study. The blood was drawn at the one and only visit for each subject) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function measured by percent predicted forced expiratory volume in the first second (FEV1%) |  | 7 months (from the start to completion of study, but FEV1% was measured at the one and only visit for each subject) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
African American children with stable asthma, Asthma severity, Interleukin 13 from PHA stimulated PBMC, Lung function (FEV1%), Total serum IgE, Pediatrics
Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children

Study Overview
=================
Brief Summary
-----------------
Levobupivacaïne (Chirocaine®) is a new local anaesthetic recently marketed in France. The goal of this prospective work is to study the pharmacokinetic aspect of this drug after injection around the sciatic nerve (subgluteal way).

Detailed Description
-----------------
The originality of this work is to call upon a modelling of pharmacokinetic by using the principle of the pharmacology of population. This work also proposes to appreciate a dynamic aspect since data of effectiveness and tolerance will be collected with regular intervals during the first 24 hours after the beginning of the study.

Official Title
-----------------
Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children

Conditions
-----------------
Surgical Pathology of the Leg or the Foot.

Intervention / Treatment
-----------------
* Drug: Levobupivacaïne


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgical pathology of the leg or the foot with garot tyre of thigh Age included between 6 months and 12 years Status ASA I or II Exclusion Criteria: Bilateral or one-sided surgical gesture realized without garot tyre Cutaneous infection in the point of draining Clinical confusion of the coagulation Allergy informed in the local anesthesics of amino-acid class Evolutionary neurological pathology of the operated limb Renal, respiratory, cardiac or hepatic insufficiency.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Levobupivacaïne|1,75mg/kg|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The purpose of this work is to describe the pharmacokinetics characteristics by the levobupivacaine after peripheral block by using the principle of the pharmacology of population, this allowing fewer sampling of blood by patients. |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appreciation, by the anaesthetist in charge of the patient, of the quality of the surgical analgesia during the surgery by: very effective, effective, ineffective. Measure of the delay of appeal of the first one bolus of morphine. |  | 24 months |
Massage of the Low Back Muscles Assessed With Ultrasound Scanning

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to use diagnostic ultrasound to compare the thickness of soft tissues in the low back in a group of patients with chronic low back pain treated with massage to a control group of non-treated patients. It is hypothesized that on average, soft tissue thickness in the lumbar region will change in the group receiving massage compared to the control group.

Detailed Description
-----------------
A specialized form of massage designed to reduce fascial restrictions will be compared to a no-treatment control group based on a change in thickness of the lumbodorsal fascia as determined by ultrasound imaging.

Official Title
-----------------
Effect of Fascial Release on Connective Tissue Structure in Human Subjects With Chronic Low Back Pain as Determined by Ultrasound Imaging: a Randomized Controlled Trial

Conditions
-----------------
Myofascial Pain Syndrome

Intervention / Treatment
-----------------
* Procedure: Specific massage for fascial release
* Other: Quiet non-instructed rest for 3 minutes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of chronic low back pain far at least 3 months Able to read and write English Between 18-64 years of age Exclusion Criteria: Prior lumbar surgery Infected or broken skin over the lumbodorsal fascia Major structural spinal deformity Specific cause of low back pain, such as tumor, infection, fracture Bleeding disorders or use of anticoagulant medications Pregnancy Litigation for low back pain Systemic infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fascial massage<br>A specific type of fascial massage to release restricted lumbodorsal fascia. | Procedure: Specific massage for fascial release<br>* Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.<br>* Other names: Superficial fascial release;|
| No Intervention: No treatment control<br>Patient will rest quietly without receiving any instruction. | Other: Quiet non-instructed rest for 3 minutes<br>* Patient will lay quietly without any instructions on how to relax.<br>* Other names: Uninstructed rest;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thickness of lumbodorsal fascia determined by ultrasound imaging |  | An average of 5 minutes from the the end of first treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myofascial pain, Trigger points
COVID-19 Seroprevalence in Pregnant Women and Blood Donors

Study Overview
=================
Brief Summary
-----------------
The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.

Official Title
-----------------
SARS-CoV-2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang

Conditions
-----------------
COVID-19 Respiratory Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women Adult female Admitted to hospital for live birth Informed consent Affiliated to the French social security health insurance scheme Blood donors Adult male or female Qualified for whole blood donation (up to 70 years old in France) Informed consent Affiliated to the French social security health insurance scheme Exclusion Criteria: Legal incapacity or limited legal capacity Subject without health insurance coverage Exclusion period of another study or exclusion period of the French national healthy volunteer registry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women<br>Women admitted to hospital for a live birth. | |
| Blood donors<br>Subjects qualified for whole blood donation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-SARS-CoV-2 spike protein total IgG | Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay | at inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-SARS-CoV-2 nucleocapsid protein total IgG | Total IgG directed against anti-SARS-CoV-2 nucleocapsid protein as measured by ELISA assay | at inclusion |
Validation of the Panic Screening Score in Patient With Unexplained Chest Pain

Study Overview
=================
Brief Summary
-----------------
Panic-like anxiety ( panic attacks with or without panic disorder), a highly treatable condition, is the most prevalent condition associated with unexplained chest pain in the emergency department. Panic-like anxiety may be responsible for a significant portion of the negative consequences of unexplained chest pain, such as functional limitations and chronicity. However, more than 92% of panic-like anxiety cases remain undiagnosed at the time of discharge from the emergency department. The 4-item Panic Screening Score questionnaire was derived in order to increase the identification of panic-like anxiety in emergency department patients with unexplained chest pain. The goals of this prospective cohort study are to (1) refine the Panic Screening Score; (2) validate the revised version of the Panic Screening Score; (3) measure the reliability of the revised version of the Panic Screening Score and (4) assess the acceptability of the instrument among emergency physicians.

Official Title
-----------------
A Prospective Cohort Study to Refine and Validate the Panic Screening Score for Identifying Panic Attacks Associated With Unexplained Chest Pain in the Emergency Department

Conditions
-----------------
Panic Attack, Noncardiac Chest Pain

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presenting unexplained chest pain as defined by: the absence of an identifiable cause (e.g., pneumothorax,pneumonia), the absence of chest trauma, the absence of new malignant cardiac arrhythmia, and a score of 2 or less on the modified version of the thrombolysis in myocardial infarction score. Exclusion Criteria: presence of a terminal illness; presence of a severe communication problem that could interfere with the administration of the questionnaire; presence of a psychotic state, a major cognitive deficit or other condition that could invalidate the interview; being legally incompetent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Emergency department patients with unexplained chest pain | Other: No intervention<br>* Validation of the Panic Screening Score<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of the Panic Screening Score |  | 3 years |
Assessment of Sleep Quality in Cannabinoid Therapy

Study Overview
=================
Brief Summary
-----------------
The current study aims to assess the impact of starting cannabinoid therapy on sleep quality for individuals with sleep disturbance.

Detailed Description
-----------------
After the initial signing of the consent form, they will complete a battery of baseline questionnaires online on sleep, including the Sleep Regularity Questionnaire, Epworth Sleepiness Scale, Insomnia Severity Index, and the Depression, Anxiety, Stress Scale (DASS-21). That night, before beginning active treatment, participants will be monitored using Cerebra's Level 2 plus ECG system (the Prodigy). After 6 weeks of active treatment, participants will again complete a night of Level 2 plus ECG recording using the Prodigy, evening, and morning questionnaires, and will repeat baseline sleep questionnaires.

Official Title
-----------------
Assessment of Sleep Quality in Patients Utilizing Cannabinoid Therapy

Conditions
-----------------
Poor Sleep Quality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria A Pittsburgh Sleep Quality Index score >5 Between the ages of 40-65 No current recreational or medical cannabis use within 4 weeks of the study initiation OR positive urine drug screen (UDS) for Tetrahydrocannabinol No use of anti-psychotics, tricyclic antidepressants, or prescription stimulants No use of medications for promoting sleep (e.g., anti-histamines, benzodiazepines, melatonin). Low risk of Obstructive Sleep Apnea (Low Risk on Berlin Questionnaire), or no presence of moderate or severe Obstructive Sleep Apnea on baseline polysomnography (AHI <15). Has been prescribed THC:CBD combination therapy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Sleep Quality (Pittsburgh Sleep Quality Index) |  | 6 weeks | 
| Change in Objective Sleep Quality (Odds Ratio Product) |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cannabinoid Therapy
Observational Study - ILM Peeling

Study Overview
=================
Brief Summary
-----------------
This observational study investigates the effects of epimacular membrane peeling on the structure and function of the retina.

Official Title
-----------------
Observational Study On Retinal Structure And Function Before And After Epimacular Membrane Peeling

Conditions
-----------------
Epimacular Gliosis, Macular Hole

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Epimacular Gliosis Must be scheduled for ILM-peeling independently of study Must be older then 18 years of age Exclusion Criteria: Visual acuity > 0,4 logMAR (< 20/50 EDTRS) Other ophthalmological disorder affecting visual acuity and/or visual field and/or retinal structure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Epimacular Gliosis Without Macular Hole<br> | |
| Epimacular Gliosis With Macular Hole<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BCVA |  | 6 months after ILM peeling | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retina, gliosis, macula, membrane, ILM
Respiratory Muscle Strength in Patients With NMD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if inspiratory muscle strength training (IMST) will impact maximal inspiratory pressure and pulmonary function in patients with neuromuscular disease.

Detailed Description
-----------------
Subjects undergo a 12-week period of inspiratory muscle strength training. Respiratory strength is assessed before and after the training period.

Official Title
-----------------
Respiratory Muscle Strength and Function in Patients With Neuromuscular Disease

Conditions
-----------------
Neuromuscular Disease

Intervention / Treatment
-----------------
* Device: Threshold PEP or IMT device Phillips-Respironics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of neuromuscular disease Clinical evidence of impaired pulmonary function Exclusion Criteria: Above or below age range No clinical evidence of impaired pulmonary function No diagnosis of a neuromusuclar disease Presence of an acute illness at time of study Participating in other research studies involving investigational drugs Diagnosis of a primary pulmonary disease Use of tobacco products

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br>Threshold PEP or IMT device Phillips-Respironics | Device: Threshold PEP or IMT device Phillips-Respironics<br>* The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal Inspiratory Pressure | The primary endpoints for inspiratory muscle training efficacy will be maximal inspiratory pressure tests, a measure of respiratory strength. | Baseline (pre-IMST) and 3 months (post-IMST) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory Muscle Strength